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Background: Alveolar macrophages, with their high functional plasticity, were reported to orchestrate the induction
and resolution of inflammatory processes in chronic pulmonary diseases. Noninvasive imaging modalities that offer
simultaneous monitoring of inflammation progression and tracking of macrophages subpopulations involved in the
inflammatory cascade, can provide an ideal and specific diagnostic tool to visualize the action mechanism in its
initial stages. Therefore, the purpose of the current study was to evaluate the role of M1 and M2 macrophages in
the resolution of lipopolysaccharide (LPS)-induced lung inflammation and monitor this process using noninvasive
free-breathing MRI and CT protocols.
Methods: Bone-marrow derived macrophages were first polarized to M1 and M2 macrophages and then labeled with
superparamagnetic iron oxide nanoparticles. BALB/c mice with lung inflammation received an intrapulmonary instillation
of these ex vivo polarized M1 or M2 macrophages. The biodistribution of macrophages subpopulations and the
subsequent resolution of lung inflammation were noninvasively monitored using MRI and micro-CT. Confirmatory
immunohistochemistry analyses were performed on lung tissue sections using specific macrophage markers.
Results: As expected, large inflammatory areas noninvasively imaged using pulmonary MR and micro-CT were observed
within the lungs following LPS challenge. Subsequent intrapulmonary administration of M1 and M2 macrophages
resulted in a significant decrease in inflammation starting from 72 h. Confirmatory immunohistochemistry analyses
established a progression of lung inflammation with LPS and its subsequent reduction with both macrophages subsets.
An enhanced resolution of inflammation was observed with M2 macrophages compared to M1.
Conclusions: The current study demonstrated that ex vivo polarized macrophages decreased LPS-induced lung
inflammation. Noninvasive free-breathing MR and CT imaging protocols enabled efficient monitoring of progression
and resolution of lung inflammation.
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Apart from their well-known role in phagocytosis and
recognition of foreign antigens, alveolar macrophages
(AM) play a key role in the induction and the resolution
of inflammatory responses characteristic of lung diseases
such as chronic obstructive pulmonary diseases (COPD)
and acute lung inflammation (ALI) [1, 2]. The termin-
ation and the resolution of lung inflammation and the
consequent tissue homeostasis are remarkably functional
and coordinated processes orchestrated by AM [3, 4].
Although the diversity of macrophage function is not yet
fully understood, it is increasingly recognized that AM
are endowed with high functional plasticity allowing
them to acquire either a classical pro-inflammatory M1
activation (M1 macrophages) or an alternatively immu-
noregulatory M2 activation (M2 macrophages) depend-
ing on the cross-talk of various signals they received
from surrounding cells or from the pathogen itself [5, 6].
While M1 macrophages are endowed with strong
tumoricidal and microbicidal activity, M2 macrophages
are implicated in containment and promotion of tissue
remodeling and disease progression [7, 8]. Taken to-
gether, macrophages populations perform homeostatic
activities such as host defense, wound healing and im-
mune regulation [9].
Thus, polarized macrophages subpopulations may
considerably help in both diagnostic purposes and evalu-
ation of therapeutic interventions through their inherent
ability to home at the inflammatory sites making them
attractive vehicles to deliver contrast agents [10]. Conse-
quently, noninvasive imaging approaches, which enable
simultaneous monitoring of inflammation progression
and tracking of a particular cell population involved in
the inflammatory cascade, can provide an ideal and spe-
cific diagnostic tool to visualize the action mechanism in
its initial stages.
Macrophage imaging using magnetic resonance im-
aging (MRI) has emerged as a promising noninvasive
tool for pre-clinical and clinical assessments of several
inflammatory diseases such as atherosclerosis and myo-
cardial infarction, stroke, multiple sclerosis, rheumatoid
arthritis, and kidney transplantation [11]. The homing of
different macrophages subsets to the inflammatory sites
has been previously demonstrated using high resolution
noninvasive MRI in a mice model bearing calf muscle
inflammation [12].
Noninvasive monitoring of macrophages trafficking to
the lung using MRI was challenging because of the diffi-
culties to image this organ (i.e. signal loss due to cardiac
pulsation and respiration, susceptibility artifacts caused
by multiple air-tissue interfaces and low proton density).
However, the technical improvements in the gradient
systems and the development of ultrashort time of echo
(UTE) MR pulse sequence [13] have made possibleattaining both high spatial resolution and good signal to
noise ratio in lungs MR images [14]. Besides, pulmonary
inflammatory diseases involving edema formation or
mucus production as observed in COPD, Asthma or
ALI [15], can be directly measured using standard gradi-
ent echo sequences [16] and with a higher sensitivity
and diagnostic usefulness using UTE in artefacts-free
images. Therefore, simultaneous noninvasive tracking of
macrophages biodistribution and monitoring of inflam-
mation progression using MRI will certainly open new
perspectives for imaging, diagnosis and treatment of sev-
eral respiratory diseases.
On the other hand, with the enhanced improvements
in computer speed and memory and the inherent X-ray
absorption contrast between lung parenchyma and gas-
eous exchange, micro computed tomography (micro-
CT) has in recent time become a powerful noninvasive
imaging technique. Micro-CT has the advantage of of-
fering the highest spatial resolution among the noninva-
sive imaging modalities thus providing information
about lung function and changing tissue characteristics
in a free-breathing rapid acquisition protocol during lon-
gitudinal follow-up studies [17]. It also allowed evaluat-
ing acute and chronic pulmonary disease models to
understand lung parenchyma and the bronchial tree
both structurally and functionally [18, 19].
In the current study, the effect of intrapulmonary admin-
istration of bone marrow derived macrophage (BMDM)
subpopulations to decrease LPS-induced lung inflamma-
tion was evaluated in a mouse model using noninvasive
free-breathing high-resolution MRI and CT protocols.
Histological analyses were performed to correlate and con-
firm the noninvasive imaging readouts.
Materials and methods
Animals and COPD model
Female Balb/c mice (20-22 g) were obtained from the
University’s main animal care center. All experiments were
performed in accordance with the National guidelines for
the care of laboratory animals and the study was approved
by the Ethical Committee of the College of Applied Medical
Sciences (agreement number: CAMS05/3334). During the
different experimental procedures, animals were anesthe-
tized by intramuscular administration of a mixture of
0.1 mL of 4 mL of ketamine (50 mg/mL), 1 mL of xylazine
(2 %), and 5 mL of physiological serum. COPD model was
induced by intrapulmonary instillation (1 mg.kg−1; V =
100 μl) of Lipopolysaccharide (LPS) from Escherichia Coli
(Santa Cruz Biotechnology, Inc., CA, USA) using a Micro-
Sprayer aerosolizer (Penn-Century Inc., PA, USA). At 48 h
post LPS challenge, mice were intrapulmonary instilled
with either physiological saline, iron labeled ex vivo polar-
ized M1 or M2 macrophages (106 cells suspended in 100 μl
phosphate buffered saline (PBS) solution).
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Bone marrow (BM) derived M1 and M2 macrophages
were obtained and polarized as previously reported [12].
Briefly, BM cells from tibiae and femora of donor mice
were incubated for 7 days at 37 °C in complete IMDM
medium containing L-glutamine and phenol red (Gibco,
Lifetechnologies, CA, USA) and supplemented with
10 ng/ml of macrophage clone stimulating factor (R&D
systems, Abingdon, UK) to obtain adherent M0 macro-
phages. Macrophage polarization was then induced by
incubating adherent M0 cells for 20 h at 37 °C in
complete IMDM medium supplemented with 1 ng.ml−1
LPS (Santa Cruz Biotechnology, Inc., CA, USA) and
10 ng.ml−1 INFγ to obtain M1-polarized cells or with
10 ng.ml−1 IL-10 and 20 ng.ml−1 IL-4 (R&D systems,
Abingdon, UK) to obtain M2-polarized macrophages.
M1 or M2 macrophages were labeled with Dextran-
coated SPIO nanoparticles (Micromod Partikeltechnolo-
gie GmbH, Germany) at an extracellular iron concentra-
tion of 2 mM with 1 h incubation time at 37 °C, which
was chosen as the best compromise between labeling effi-
ciency and biocompatibility to the cells. For efficient mac-
rophages labeling, SPIO nanoparticles were functionalized
by the addition of polyethylene glycol (PEG) with amine
terminal (NH2) [20]. We have previously reported that
these nanoparticles showed an enhanced labeling effi-
ciency of macrophages with a better biocompatibility [21].
Macrophages were incubated in serum-free RPMI
medium containing L-glutamine and phenol red (Gibco,
Lifetechnologies, CA, USA) to avoid proteins interac-
tions with the uptake mechanism [22]. The incubation
step was followed by an overnight chase period in SPIO-
free culture medium to allow sufficient time for iron
oxide internalization. Prior to administration, iron content
in the different macrophages subsets were quantified
using Ferrozine-based assay and their biocompatibility
was assessed using MTTassay as previously reported [21].
Ferrozine is an iron-chelating agent that forms a com-
plex with iron and exhibits characteristic UV/Vis ab-
sorption. By comparing to a standard calibration curve,
accurate quantification of iron uptake by macrophages
can be obtained. Briefly, 2x105 labeled M1 or M2 macro-
phages were digested with 5 M hydrochloric acid and
absorbance was measured at 351 nm using Multiskan
Go Spectrophotometer (Thermo Scientific, NH, USA).
Using a calibration curve of the absorbance vs. iron con-
centration of the SPIO nanoparticles prepared under the
same experimental protocol, the iron content in the
macrophages was determined and expressed as pg of
iron per cell.
Cell viability was evaluated by MTT (3-[4,5-dimethyl-
thiazol-2-yl]-2,5- diphenyltetrazolium bromide) Cell Growth
Assay Kit (Merck Millipore, MA, USA) according to the
manufacturer protocol. Briefly, iron labeled M1 and M2macrophages (104 cells/well) were placed in a 96-well plate
(n = 3) and absorbance was measured using Multiskan Go
Microplate Spectrophotometer (Thermo Scientific, NH,
USA) with a test wavelength of 570 nm and a reference
wavelength of 630 nm. The relative percentage of cell
viability for each condition was calculated related to
unlabeled M1 and M2 macrophages.Magnetic resonance imaging
To noninvasively monitor the biodistribution of M1 or M2
iron-labeled macrophages subpopulations in LPS-induced
pulmonary model, mice were imaged using a 4.7 T Phar-
mascan 47/16 Bruker magnet interfaced to ParaVision 5.1
software (Bruker Biospin GmbH, Rheinstetten, Germany).
A free-breathing MR imaging protocol was optimized to
allow simultaneous detection of macrophages subsets and
the visualization of inflammation progression in the lung
using a radial UTE sequence (TR/TE = 100/0.4 ms) with
100 x 100 μm pixel resolution according to the protocol
previously reported [23]. Pulmonary MRI was performed
on mice (n = 6 per group) before LPS challenge (Control),
48 h post LPS challenge (LPS) chosen as time 0 for investi-
gating the effect of macrophages intrapulmonary adminis-
tration on the resolution of lung inflammation, and at 4 h,
24 h, 48 h, 72 h and 168 h after either iron-labeled M1 or
M2 macrophages subsets administration (LPS +M1 or
LPS +M2, respectively). A set of 12 consecutive axial slices
with 1 mm thickness were positioned approximately at the
same level for all the animals in order to cover the whole
lung volume during the 1-week follow-up study.
MR images were analyzed with freeware medical
image analysis software (MIPAV, National Institutes of
Health, Bethesda, MD, USA). The inflamed lung volume
(ILV) was quantified with a semiautomatic segmentation
procedure [14]. Briefly, a low-intensity threshold was
applied to exclude the non-inflamed regions from the
lung images. LPS-induced inflammatory regions were
extracted with a semiautomatic tool capable of generat-
ing contours whilst moving over the different lung
structures by recognizing the intensity level of each
pixel and selecting regions according to the default pre-
set parameters (MIPAV ‘LevelSet’ active-contour algo-
rithm). The total volume of high-intensity signals was
computed by multiplying the slice thickness by the sum
of all the areas segmented in the 12 consecutive slices.
The segmentation parameters were the same for all the
analyzed images, chosen to segment regions corre-
sponding to high-intensity signals. As the signals from
the LPS-induced edema and the vessels were of com-
parable intensities, the volume corresponding to the
vessels was assessed on control images and then sub-
tracted from the volumes determined on post-challenge
images.
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To monitor using an alternative noninvasive imaging
modality the progression of LPS-induced inflammation
and assess the possibility of inflammation resolution
after intrapulmonary administration of either M1 or M2
macrophages subpopulations, mice (n = 6 per group)
were scanned using a dedicated small animal high reso-
lution micro-CT scanner (SkyScan 1176, Kontich,
Belgium). The following parameters were used: 50 kV,
1 mm Al filter, 385 μA source current, 600 ms exposure
time. Micro-CT imaging was only performed at 24 h,
72 h and 168 h post-macrophages administration on the
same mice, which were previously imaged using MRI.
Mice were allowed to recover for 4 to 6 h after the MRI
acquisitions. CT scans were limited to three time points
during the 1-week investigation to avoid high radiation
exposure to the mice (i.e. ~ 0.1Gy per scan) that were
imaged at the different investigation time points. Projec-
tion images were recorded in steps of 0.5 degrees from 0
to 360 degrees. Images were acquired throughout the
spontaneous respiratory cycle. Respiratory motions were
recorded with a visual camera, detecting the up- and
downward movement of the thorax and then translated
into a pseudo-sinusoidal signal to allow retrospective re-
spiratory gating. 3D acquisitions with a 18 μm isotropic
resolution were performed to cover the entire lung for a
total acquisition time of 24 min. Images were recon-
structed with SkyScan NRecon software (version 1.6.9.4)
using a Feldkamp cone-beam reconstruction algorithm.
Reconstruction parameters were smoothing “6”, beam-
hardening correction “22 %”; post-alignment and ring
artifact correction were optimally set for each individual
scan. Reconstructed 3D images have a total of 864 slices
with isotropic 18 μm voxel size and 1024 × 1024 reso-
lution. A water phantom was used to calibrate the image
to Hounsfield units (HU). Lungs were automatically de-
lineated in the 3D micro-CT images as previously de-
scribed [24] and the airways were removed from the
lung delineation [25]. Inflamed lung volume (ILV) was
finally measured on the segmented lungs to quantify the
level of LPS-induced inflammation detected using CT
and subtracted from values quantified in control mice to
exclude the volume corresponding to the vessels and
correlate with MRI readouts.
Immunohistochemistry
Lungs (n = 3 in each group and at each time point) were
directly removed after the micro-CT scanning and fixed
overnight in 4 % paraformaldehyde. Processing of tissues
for histological analyses was performed on sets of con-
secutive 5 μm thick sections. F4/80 rat monoclonal anti-
body (1:100) as universal marker for macrophages, NOS2
rabbit polyclonal antibody (1:1000) and Arginase goat
polyclonal antibody (1:100) (Santa Cruz Biotechnology,Inc., CA, USA) as marker for M1 and M2 macrophages
respectively, were applied as primary antibodies. Respect-
ive mouse ABC staining systems were used as sources for
secondary antibodies (Santa Cruz Biotechnology, Inc., CA,
USA) and consequent detection was performed as per
manufacturer’s instructions. Slides were counterstained
with hematoxylin before being observed using a BX53
Olympus microscope and analyzed using CellSens Entry
digital imaging software (Olympus Corporation, Tokyo,
Japan).
Statistical analysis
Data were presented as the mean standard deviation.
ANOVA with post-hoc analyses were performed using
SPSS software v12.0 (SPSS Inc., Chicago, IL, USA) to
compare ILV assessments among the different groups. A
p-value < 0.05 was considered significant for all tests.
Results
Prior to their in vivo administration, M1 and M2 label-
ing efficiency and viability were evaluated. Quantification
of iron content revealed an uptake of 17.68 ± 0.95 and
21.12 ± 1.25 pg/cell for M1 and M2 macrophages, re-
spectively, under the used experimental conditions,
while showing 99.72 ± 2.5 % and 99.38 ± 1.6 % of relative
cell viability.
Pulmonary MR images acquired using UTE sequence,
at 48 h post LPS challenge with 1 mg.kg−1, allowed the
detection of large inflammatory areas in the lung
(Fig. 1a). At this time point, the average inflamed lung
volume measured in the LPS group was 50.4 ± 3.7 μl and
found to decrease slightly during the 1-week investiga-
tion to reach 43.8 ± 5.3 μl, whereas the average quanti-
fied value of ILV was 1.8 ± 3.9 μl in the control group
(Fig. 1b). Following intrapulmonary administration of ei-
ther M1 or M2 macrophages, void signal dots, related to
the presence of iron-labeled macrophages were detected
in the lung (red arrows in Fig. 1a) at 24 h post adminis-
tration. Interestingly, a statistically significant decrease
in inflammation was detected starting from 72 h post
intrapulmonary administration of M2 macrophages with
ILV equal to 22.8 ± 4.1 μl and 11.6 ± 4.2 μl at 72 h and
168 h, respectively, compared to 47.8 ± 4.9 μl for LPS
group before M2 macrophages administration. However,
a lower effect was observed with M1 macrophages sub-
sets, which was statistically different at 168 h post ad-
ministration. At this time point, ILV decreased from
43.8 ± 5.3 μl for LPS group to 35.6 ± 3.9 μl after M1
macrophages administration.
Similarly, micro-CT images acquired at 24 h post
LPS challenge allowed the detection of inflammation
with ILV = 82.1 μl in LPS group compared to ILV =
3.9 μl in Control group, as assessed using CT quantifi-
cation, (Fig. 2). Following macrophages administration,
Fig. 1 Lung Magnetic Resonance Imaging. a- Representative axial MR images of Control, LPS, LPS + M and LPS + M2 groups at 24 h, 72 h and
168 h post intrapulmonary administration of either M1 or M2 bone-marrow derived macrophages subpopulations. Red arrows highlight the presence
of void signal dots, related to the presence of iron-labeled macrophages co-localized with inflammatory regions in the lung. b- Quantification of
inflamed lung volume (ILV) for the different groups during the 1-week follow-up investigation. Data expressed as mean ± SD, n= 6 per group. * p< 0.05.
**p < 0.01
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with M2 macrophages subsets starting from 72 h post
intrapulmonary administration corresponding to 41.2 %
decrease in ILV compared with LPS group at the same
time point. M1 macrophages subsets were found to pro-
duce a statistically significant attenuation in ILV at 1-week
investigation time point. CT did not allowed direct
visualization or detection of macrophages subpopulations
even with its very high 3D isotopic resolution of 18 μm.An excellent correlation was found between the quan-
tification of ILV assessed using either MRI or CT with a
correlation coefficient of 0.919, 0.9693 and 0.9115 at
24 h, 72 h and 168 h investigation time points, respect-
ively (Fig. 3).
To investigate the effect of intrapulmonary administra-
tion of ex vivo polarized macrophages subtypes on the
attenuation of lung inflammation, immunohistochemis-
try analyses were also performed to confirm noninvasive
Fig. 2 Lung Computed Tomography imaging. a- Representative axial micro-CT images of Control, LPS, LPS + M1 and LPS +M2 groups at 24 h,
72 h and 168 h post intrapulmonary administration of either M1 or M2 bone-marrow derived macrophages subpopulations. b- Quantification of
inflamed lung volume (ILV) for the different groups during the 1-week follow-up investigation. Data expressed as mean ± SD, n = 6 per group.
* p < 0.05. **p < 0.01
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with LPS, LPS +M1 and LPS +M2 compared to Control
mice. IHC analyses (Fig. 4) revealed strong accumulation
of inflammatory cells, changes in alveolar walls and air-
way narrowing. While LPS induced considerable inflam-
mation in the lungs over time compared to controls,
administration of macrophages seems to have counter-
acted the inflammation by helping the lungs revert to
their normal histology. The intrapulmonary administra-
tion of either M1 or M2 macrophages revealed an at-
tenuation of inflammation with a more prominent effect
observed following instillation of M2 macrophages (i.e.,Arginase1 marker) compared to mice receiving M1 mac-
rophages (i.e., NOS2 marker). Considerable attenuation
of lung inflammation was evident histologically post
macrophages instillation.
Discussion
This study evaluated the possibility of enhanced resolution
in LPS-induced lung inflammation following intrapulmon-
ary administration of ex vivo polarized M1 and M2 bone
marrow derived macrophages. Free-breathing noninvasive
MR and CT imaging acquisitions along with confirmatory
histological analyses were used to monitor this process.
Fig. 3 MRI vs. CT correlation. Correlation plot of the inflamed lung volume (ILV) quantified using both MRI and CT at a- 24 h; b- 72 h and c-168 h
investigation time points. ⌧: control, ●: LPS, ■: LPS + M1, ▲: LPS + M2
Fig. 4 Immunohistochemistry (IHC) analyse. Representative lung images of Control, LPS, LPS + M1 and LPS +M2 at 24 h, 72 h and 168 h
post-intrapulmonary administration of either M1 or M2 bone-marrow derived macrophages subpopulations a- NOS2 b- Arginase1 staining
Al Faraj et al. BMC Medical Imaging  (2015) 15:16 Page 7 of 9
Al Faraj et al. BMC Medical Imaging  (2015) 15:16 Page 8 of 9We have recently demonstrated the possibility of non-
invasive tracking the preferential migration of differently
polarized macrophages after their intravenous injection
to the sites of inflammation in the lung [23]. In the
current study, following their intrapulmonary instilla-
tion, iron labeled M1 and M2 macrophages subsets were
successfully detected in MR images as void signal dots
up to 24 h post administration. Macrophages were found
to co-localize with the inflammatory regions simultan-
eously detected as hyper-intensity signal in artifact-free
images using UTE sequence. Void signal dots were not
perceived at later investigation time point, most prob-
ably because of the biodegradation of iron oxide nano-
particles by the macrophages. It was previously reported
that the T1 and T2 relaxivities of iron oxide nanoparti-
cles, which allow their noninvasive detection using MRI,
decreased following internalization into macrophages
and their subsequent degradation [26].
On the other hand, LPS-induced lung inflammation,
which was reported to peak at 48 h post LPS challenge
and manifested in edema secretion resulting from gener-
alized granulocytic (especially neutrophilic) inflamma-
tion [27], was chosen as the time point to investigate the
enhanced resolution of lung inflammation following
macrophages intrapulmonary administration.
Inflamed lung volume, reported using both MRI and CT,
revealed a considerable increase in inflammation following
LPS treatment. An enhanced resolution of pulmonary in-
flammation quantified by a statistically significant decrease
in ILV was observed following administration of M2 mac-
rophages starting from 72 h post administration (i.e.
52.3 % to 73.5 % decrease as assessed by MRI at 72 h and
168 h, respectively) and to a lower extent with M1 macro-
phages 1-week post administration (i.e. 18.7 % decrease).
With its higher spatial resolution, ILV assessed by CT was
found higher as compared with MRI readouts. However,
quantification results obtained using both noninvasive im-
aging modalities, performed under free-breathing protocol,
were perfectly correlating.
Corroborating the findings of MRI and CT, we de-
tected through histology the successful buildup of exter-
nally administered macrophages through demonstration
of F4/80, a universal marker for these cells (data not
shown). In addition, successful homing of both M1 and
M2 macrophages subsets was demonstrated through the
identification of iNOS and Arginase1 markers, respect-
ively. Architectural changes in the lungs have been
clearly demonstrated with LPS along with enhanced re-
cruitment of macrophages [28]. Lung inflammation was
found to decrease gradually in a time dependent manner
following intrapulmonary administration of macrophages
subsets with a statistically significant attenuation ob-
served as early as 72 h in LPS +M2 group (p < 0.01) and
by 7 days in LPS +M1 group (p < 0.05). These observationsconfirmed the potential role of ex vivo polarized bone mar-
row derived macrophages subsets in the attenuation of in-
flammation. In addition, it is important to note that the
presence of iron oxide labeled macrophages after instilla-
tion has been confirmed in lung histology sections and the
results were published elsewhere [23, 29].
Studies have reported that macrophage polarization is
based on the levels of various cell signals which drive mac-
rophages to continuously switch from M1-proinflammatory
to M2-immunomodulating functions and vice versa to help
in regulating and resolving inflammation [1–3, 6]. While
the process involving the initiation and amplification of
the inflammatory responses were extensively studied,
the mechanisms favoring the resolution of lung inflam-
mation is not completely understood. Different mecha-
nisms were proposed for the suppression of LPS-induced
inflammation. Lonescu et al. [30] suggested that soluble
factors secreted by mesenchymal stem cells may promote
the resolution of lung injury in part by modulating alveo-
lar macrophage function. Do-Umehara et al. [31] reported
that the transcription factor Miz1 was involved in the ter-
mination of LPS-induced inflammation. D’Alessio et al.
[32] suggested that monocyte-derived iNOS plays a pivotal
role in mediating resolution of inflammation by modulat-
ing lung immune responses, thus facilitating the clearance
of alveolar inflammation and promoting lung repair. A
more recent study by Mauer et al. reported that IL-6 pro-
duction by M1 macrophages might lead to a switch from
M1 to M2 macrophages in order to resolve the inflamma-
tion [33].
Conclusions
In conclusion, ex vivo polarized M2 bone marrow de-
rived macrophages were found to enhance the resolution
of LPS-induced lung inflammation. Noninvasive imaging
modalities used in the current study can have the advan-
tage of performing longitudinal follow-up studies on dis-
ease progression and providing detailed information on
the location and extension of the pathology. The study
findings may open new therapeutic options by using
bone marrow derived macrophages for reducing tissue
inflammation. However, the potential cell signals se-
creted by macrophages and their mechanism of action in
target tissue sites need further evaluation in both pre-
clinical and clinical settings on a larger scale.
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